Medical technology for comprehensive DNA analysis in tuberous sclerosis

We performed a comprehensive molecular genetic examination of 76 patients with tuberous sclerosis. For establish molecular diagnosis of the disease, we applied a new medical technology that includes targeted high-throughput parallel DNA sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA), and Sanger sequencing. Search for point mutations and small indels in the TSC1 and TSC2 genes was carried out with next generation sequencing on the Ion S5 instrument. In order to filter out sequencing artifacts, to establish pathogenicity of the detected single nucleotide substitutions, and to identify familial cases, Sanger sequencing was performed. To search for extended deletions, the MLPA method was used. In 46% cases mutations have been detected, 70% in the TSC2 gene, and 30% in the TSC1 gene. Overwhelming majority of mutations were detected by NGS (91.9%), and 8.1% were detected by MLPA.

туберозный склероз, ген TSC1, ген TSC2, медицинская технология, высокопроизводительное параллельное секвенирование ДНК, MLPA, tuberous sclerosis, TSC1 gene, TSC2 gene, medical technology, NGS, MLPA

1. Islam, M.P. and E.S. Roach, Tuberous sclerosis complex. Handb Clin Neurol, 2015. 132: 97-109.

2. Populo, H., J.M. Lopes, and P. Soares, The mTOR signalling pathway in human cancer. Int J Mol Sci, 2012. 13(2):1886-918.

3. Huang, J. and B.D. Manning, The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J, 2008. 412(2):179-90.

4. Fokkema, I.F., et al., LOVD v.2.0: the next generation in gene variant databases. Hum Mutat, 2011. 32(5):557-63.

5. Stenson, P.D., et al., Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat, 2003. 21(6):577-81.

6. Landrum, M.J., et al., ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res, 2018. 46(D1):D1062-D1067.

7. Lek, M., et al., Analysis of protein-coding genetic variation in 60,706 humans. Nature, 2016. 536(7616):285-91.

8. Wang, K., M. Li, and H. Hakonarson, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res, 2010. 38(16):e164.

9. Robinson, J.T., et al., Integrative genomics viewer. Nat Biotechnol, 2011. 29(1):24-6.

10. Northrup H, K.M., Pearson DA, et al., Tuberous Sclerosis Complex. 2015.

11. Curatolo, P., et al., Genotype/Phenotype Correlations in Tuberous Sclerosis Complex. Semin Pediatr Neurol, 2015. 22(4):259-73.

12. Sancak, O., et al., Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet, 2005. 13(6):731-41.

13. Tyburczy, M.E., et al., Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet, 2015. 11(11):e1005637.

14. Rosset, C., C.B.O. Netto, and P. Ashton-Prolla, TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review. Genet Mol Biol, 2017. 40(1):69-79.